Skip to Content

Naoto Tada Ueno, M.D., Ph.D., F.A.C.P.

Present Title & Affiliation

Primary Appointment

Section Chief, Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Executive Director, The University of Texas MD Anderson Cancer Center Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX

Bio Statement


I have a strong background in translational breast cancer research in the areas of cancer biology and molecular therapeutics, with specific training and expertise in the key research areas of EGFR/ERK signaling and in vivo modeling. As a Ph.D. student at The UT Graduate School of Biomedical Sciences, I carried out preclinical research on the role of the HER2 pathway in chemosensitization of paclitaxel in breast cancer. In addition to my basic research background, I trained as a medical oncologist at MD Anderson and simultaneously learned how to conduct clinical research and perform data analysis related to breast cancer. I am now a practicing physician who has experience in conducting both targeted and gene therapy clinical trials.  

Since becoming a faculty member at MD Anderson, I have expanded my research to include the EGFR/ERK pathway in both breast and ovarian cancer (HER2, JNK, TIG1, FOXO3, epigenetic,etc.). Over the past 10 years, I have successfully managed projects in breast cancer biology related to triple-negative breast cancer, inflammatory breast cancer, metastasis, cancer stem cells, and drug resistance of cancer cells.  Currently I serve as an executive director of Morgan Welch Inflammatory Breast Cancer (MWIBC) Research Program and Clinic and Section of Translational Breast Cancer Research (TBCR). MD Anderson MWIBC is the world’s largest IBC specific resarch program that conducts IBC-specific clinical trials, understanding the aggressiveness of caners by studying cancer stem cells, and the impact of microenviroment (infllmationn and immunolgoical efect). For the section of TBCR, the program focuses on reducing the suffering of breast cancer patients through our unique, rapid drug development platforms via enhanced value of novel therapeutic approach and guiding to investigator-initiated clinical trials or standard of care.

Education & Training

Degree-Granting Education

1999 The University of Texas Graduate School of Biomedical Sciences, Houston, TX, PHD, Cancer Biology
1989 Wakayama Medical College, Wakayama,, Japan, MD, Doctor of Medicine

Postgraduate Training

7/1993-6/1996 Clinical Fellowship, Medical Oncology and Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1991-6/1993 Clinical Residency, Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
7/1990-4/1991 Clinical Internship, Internal Medicine, Montefiore University Hospital - University of Pittsburgh, Pittsburgh, PA
4/1989-3/1990 Clinical Internship, Rotating Internship, United States Naval Hospital, Yokosuka, Kanagawa, Japan

Board Certifications

1995 American Board of Internal Medicine - Medical Oncology, Recertification Date: 2015
1993 American Board of Internal Medicine - Internal Medicine, Recertification Date: 2014


Institutional Committee Activities

Vice Chair, M. D. Anderson Associates, 2000-2001

Honors and Awards

2013-2014 Regents Outstanding Teaching Award, The University of Texas System
2012-present Waun Ki Hong Award for Excellence in Team Science, Division of Cancer Medicine Faculty Recognition and Awards Program

Last updated: 4/26/2016